1

Louise Mehrotra
Vice President, Investor Relations

Note on Forward-looking Statements

These presentations contain forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. The viewer is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to, general industry conditions and competition; economic factors, such as interest rate and currency exchange rate fluctuations; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; challenges to patents; significant adverse litigation or government action; impact of business combinations; financial distress and bankruptcies experienced by significant customers and suppliers; changes to governmental laws and regulations and domestic and foreign health care reforms; trends toward health care cost containment; increased scrutiny of the health care industry by government agencies; changes in behavior and spending patterns of purchasers of health care products and services; financial instability of international economies and sovereign risk; disruptions due to natural disasters; manufacturing difficulties or delays; and product efficacy or safety concerns resulting in product recalls or regulatory action. A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of Johnson & Johnsons Annual Report on Form 10-K for the fiscal year ended January 1, 2012. Copies of this Form 10-K, as well as subsequent filings, are available online at www.sec.gov, www.investor.jnj.com or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statements as a result of new information or future events or developments.)
3

Note on Non-GAAP Financial Measures

These presentations may refer to certain non-GAAP financial measures. These non-GAAP financial measures should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures. A reconciliation of these non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in the Investor Relations section of the Companys website at www.investor.jnj.com.

New Molecular Entities

These presentations contain statements about new molecular entities (NMEs) and other medicines or line extensions in various stages of development. These statements are based on the Companys current knowledge of the status of development of these NMEs, medicines and line extensions and are subject to the challenges and difficulties inherent in product development. The Company assumes no obligation to update any statements regarding these NMEs, medicines or line extensions as a result of new information or future events or developments. In biopharmaceuticals, there are higher possibilities of encountering infringement claims by competitors with respect to patents or other intellectual property rights. The Company assumes no obligation to update any statements as a result of new information or future events or developments.

Strategic Partnerships, Collaborations and Licensing Arrangements

During the course of this mornings presentations, we will discuss a number of products and compounds developed in collaboration with strategic partners or licensed from other companies. Following is an acknowledgement of those relationships. Neuroscience: INVEGA SUSTENNA/XEPLION includes technology licensed from Alkermes, Inc.; RISPERDAL CONSTA developed in collaboration with Alkermes, Inc.; Bapineuzumab is being developed through a collaboration between Janssen Alzheimer Immunotherapy and Pfizer Inc.; NUCYNTA co-developed with Grnenthal GMBH Cardiovascular/Metabolism: XARELTO co-developed with Bayer HealthCare; Canagliflozin licensed from Mitsubishi Tanabe Pharma Corporation; Aciphex /PARIET licensed from Eisai Co. Ltd. Immunology: REMICADE and SIMPONI marketing partners are Schering-Plough (Ireland) Company, a subsidiary of Merck & Co., Inc. and Mitsubishi Tanabe Pharma Corporation; Sirukumab developed in collaboration with GlaxoSmithKline; ASP015K licensed from Astellas Pharma Inc. Infectious Diseases & Virology: Simeprevir (TMC 435) developed in collaboration with Medivir AB; INCIVO developed by Janssen in collaboration with Vertex Pharmaceuticals and Mitsubishi Tanabe Pharma Corporation Oncology: VELCADE developed in collaboration with Millennium: The Takeda Oncology Company; Ibrutinib (PCI32765) developed in collaboration with Pharmacyclics, Inc.; Daratumumab licensed from Genmab A/S; ZYTIGA licensed from BTG International Ltd.
6

Dominic Caruso
Vice President, Finance Chief Financial Officer

Joaquin Duato
Worldwide Chairman, Pharmaceuticals

Transforming Our Business to Transform the Lives of Patients

Pharmaceuticals is an attractive market
2011: $950 Billion global market 2016: approximately $1.2 Trillion
~5.2% CAGR

Executing well against our strategic priorities

Launched 8 new products since 2009 Leveraging a revitalized, industry-leading portfolio

Focusing on innovation and transforming patients lives globally

Source: IMS Global Market Prognosis, September 2012

10

Johnson & Johnson Growth Drivers

Creating Value through Innovation Global Reach/Local Focus Excellence in Execution Leading with Purpose

11

Creating Value through Innovation

Transforming Our Business
WW Pharmaceuticals: Operational Sales Change vs. Prior Year* 11.3%

Q109

Q309

Q110 Q310 Q111 Q311 Q112 Q312

* Q409 and Q410 change adjusted for dynamics of 53rd week

12

Creating Value through Innovation

Transforming Our Product Portfolio
Core growth products New products launched from 2009 and onwards Mature/regional products

18% 41% 52% 82%

40% 34% 26%

7%

2006
Internal data

2011

2016

13

Creating Value through Innovation

Key Products Driving Therapeutic Area Growth
WW 2012 YTD NTS Sales in Billions; Operational Growth

+19%
$5.9 $5.0 $1.4

+18%
$1.6 $1.5

+29%
$1.8

+28%

$1.4 $1.1

2011

2012

2011

2012

2011

2012

2011 HIV

2012

Immunology
Internal data

Long-Acting Antipsychotics

Oncology

14

Creating Value through Innovation

REMICADE: Solid market position, sustaining growth
16 indications and counting
EU pediatric ulcerative colitis, approved Q1 2012

1.7 million+ patients treated worldwide

1 million US patients treated; milestone reached in October
YTD TOTAL SALES OPERATIONAL GROWTH

Solid market position: 75% share of the US market for IV immunology products* Sustaining growth
8.5% YTD in the US (not including export sales) 25% QTD** in the reacquired territories

$4.6 Billion

15.1%

Exclusivity: 2018 in US; 2015*** in EU

* Source: IMS Health ** Only includes territories reacquired in Q311 *** Filed for 6 month extension that would extend our exclusivity to 2/12/15 in majority of EU countries

15

Creating Value through Innovation

STELARA: Game-changing therapy, gaining share
Game-changing therapy for the treatment of moderate to severe plaque psoriasis
Awarded International Prix Galien, October 2012

Gaining share in US Dermatology: 25.5%, up +3 points vs. 3Q11; G5 share is 24%,up +6 points from 2Q11 5-year efficacy and safety data Phase 3 programs in psoriatic arthritis and Crohns disease

YTD TOTAL SALES

OPERATIONAL GROWTH

$756 Million

46%

Source: IMS Health, DDD

16

Creating Value through Innovation

SIMPONI: Building momentum, expanding indications
Launched in 2009 for RA, psoriatic arthritis and ankylosing spondylitis Approvals in 57 countries and growing; recently launched in Japan Ulcerative colitis submitted in US and EU; PDUFA date: May 2013 Intravenous formulation in RA submitted in US and EU; PDUFA date: July 2013
YTD TOTAL SALES OPERATIONAL GROWTH

$426 Million

50%

17

Creating Value through Innovation

INVEGA SUSTENNA/XEPLION: Accelerating Our long-acting antipsychotics franchise
Launched INVEGA SUSTENNA in the US in 2009; available in 37 countries OUS as XEPLION Accelerating the growth of the Long-Acting antipsychotics franchise to 18% Significant expansion of prescriber and patient base, many of whom are new to Long-Acting category Ongoing clinical development of 3-month formulation for INVEGA SUSTENNA
YTD TOTAL SALES OPERATIONAL GROWTH

$568 Million

136%

18

Creating Value through Innovation

ZYTIGA: Most successful oral oncology launch
#1 Global oral oncology launch Approved in more than 50 countries for post-chemo metastatic castration-resistant prostate cancer (mCRPC) Penetration in the US chemo refractory setting has grown to 75% from 40% at the time of ZYTIGA launch Estimated patient share in the chemo refractory market in the US is ~67% in 3Q12; G5 is ~81% in 2Q12 US and EU regulatory filings pending for chemo-nave indication; PDUFA date: mid-December 2012
Chemo-nave mCRPC market is 3X the size of post-chemo

YTD TOTAL SALES

OPERATIONAL GROWTH

$697 Million

372%

Source: IMS Health, DDD 19

Creating Value through Innovation

VELCADE: Launching subcutaneous formulation
First-in-class proteasome inhibitor for multiple myeloma Subcutaneous administration approved 2012 in EU and Canada Pursuing additional indications: Mantle Cell Lymphoma

YTD TOTAL SALES

OPERATIONAL GROWTH

$998 Million

16%

20

Creating Value through Innovation

PREZISTA: A leading Protease Inhibitor with robust growth
First approved in 2006 for treatment-nave and experienced HIV patients Leading protease inhibitor in Europe and #2 in US Awaiting approval for single 800mg tablet
YTD TOTAL SALES OPERATIONAL GROWTH

$1.1 Billion

24%

Source: IMS Health, NPA and DDD Database

21

Creating Value through Innovation

INCIVO: Regaining traction following strong initial uptake
Approved by the European Medicine Agency in 2011 Achieved reimbursement more than 100 days faster than the European benchmark (141 vs. 252 days) Sales trends show strong initial uptake in urgent to treat/warehoused patients Seasonality pattern of slowing Q1 to Q3 sales, with pick-up seen in September With 67% share, continuing to maintain a strong lead vs. boceprevir across Europe

CONTRIBUTED 3.3% TO YTD OUS PHARMACEUTICAL OPERATIONAL GROWTH

Source: IMS

22

Creating Value through Innovation

XARELTO: Broadest profile, new indications pending
Broadest indication profile of any of the newer oral anticoagulants Positive gains in access:
93% coverage on commercial formularies 90% of Medicare Part D lives
CONTRIBUTED 1.6% TO YTD US PHARMACEUTICAL GROWTH

# 1 preferred brand among Cardiologists for AF and among Orthopedic Surgeons for Orthopedic use* Additional indications in DVT / PE and ACS pending with FDA Capturing 53% NBRx of novel oral anticoagulants in AF**
* September 2012 proprietary ATU survey ** Source: IMS

23

Johnson & Johnson Growth Drivers

Creating Value through Innovation Global Reach/Local Focus Excellence in Execution Leading with Purpose

24

Global Reach/Local Focus

Broadening Geographic Presence

US

35% 51% 65% 49%

OUS

2006

2011

US vs. OUS Overview: Sales as % of Total Pharmaceuticals

25

Global Reach/Local Focus

Growing in Emerging Markets

7%

14%

Developed Emerging

93%

86%

2006

2011

Sales as % of Total Pharmaceuticals

26

Johnson & Johnson Growth Drivers

Creating Value through Innovation Global Reach/Local Focus Excellence in Execution Leading with Purpose

27

Excellence in Execution
US Pharmaceutical Sales Generated from 2009-2012 Product Launches
Sales from 2009-Q2 2012, Product Launches through June 2012
RANK 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
Source: IMS National Sales Perspectives, Jun 2012, Rx only

COMPANY JOHNSON & JOHNSON PFIZER SANOFI NOVARTIS TAKEDA VERTEX PHARMA BRISTOL-MYERS SQB. NOVO NORDISK BOEHRINGER INGEL AMGEN TEVA LILLY MERCK & CO GLAXOSMITHKLINE UCB

($MM) $3,388 $2,187 $2,143 $1,883 $1,782 $1,602 $1,491 $1,261 $1,222 $964 $786 $730 $728 $658 $550

28

Excellence in Execution
Market Performance: EMEA (Europe, Middle East and Africa)
Janssen Is the Fastest Growing Top 20 Company in EMEA
EMEA top 20 pharmaceutical companies growth rate (%) YTD June 2012 vs. PY
EMEA Janssen Gilead Novo Nordisk Bristol-Myers Squibb Boehringer Ingel Abbott Teva Merck & Co Menarini Roche Servier Bayer Novartis Merck KGAA Sanofi GlaxoSmithKline Pfizer Takeda AstraZeneca Lilly 1

11
7 5 4 3 3 2 1 -1 -1 -2 -2 -2 -3 -4 -5 -6 -8 -13 -15

Janssen 2Q12 EMEA sales rank is 7 and quarter growth ranked at 1 in the top 20 companies and has an Evolution Index of 110. Source: IMS MIDAS.

29

Excellence in Execution
Market Performance: Japan
Janssen Is the Fastest Growing Top 25 Company in Japan
Japan top 25 pharmaceutical companies growth rate (%) YTD June 2012 vs. PY
2

17
9 9 7 5 5 4 3 3 3 2 1 0 0 -1 -1 -2 -2 -3 -3 -10

Janssen 2Q12 Japan sales rank is 22 and quarter growth ranked at 1 in the top 25 companies and has an Evolution Index of 122. Source: IMS MIDAS.

30

Transforming Our Business to Transform the Lives of Patients

In Summary
Leveraging a revitalized and industry-leading portfolio Driving growth from core brands Achieving strong growth from new products launched in 2009-2012 Broadening geographic reach

31

32

Paul Stoffels, M.D.

Chief Scientific Officer

33

An Enterprise Approach to Innovation

Adopting an end-to-end strategy Accessing the best science internal or external Ensuring operational excellence Deploying world class expertise and talent Leveraging capabilities across sectors for impact on healthcare

34

Creating Value Through Innovation

Pharmaceuticals: End-to-End Strategy Focused on Five Therapeutic Areas

NEUROSCIENCE
Alzheimers disease Mood disorders Schizophrenia Chronic pain

CARDIOVASCULAR & METABOLISM

Cardiovascular disease Diabetes Heart failure

IMMUNOLOGY
Inflammatory bowel disease Rheumatoid arthritis Psoriasis Pulmonary

ONCOLOGY
Prostate Lung B-cell malignancies Breast

INFECTIOUS DISEASES & VACCINES

HIV HCV Influenza Vaccines

35

Creating Value Through Innovation

Leading Portfolio of New, Differentiated Medicines
NEUROSCIENCE CARDIOVASCULAR & METABOLISM
IMMUNOLOGY

ONCOLOGY

INFECTIOUS DISEASES & VACCINES

Launched in 2011
36

Creating Value Through Innovation

Exciting Late Stage Pipeline of New, Differentiated Medicines
NEUROSCIENCE CARDIOVASCULAR & METABOLISM
IMMUNOLOGY

ONCOLOGY

INFECTIOUS DISEASES & VACCINES

INVEGA SUSTENNA: (3 month formulation) Schizophrenia Fulranumab1,2: Pain

XARELTO: VTE, ACS Canagliflozin: Type 2 diabetes, fixed dose combination with Metformin

SIMPONI: RA (IV), UC & JIA STELARA: PsA, CD & RA Sirukumab: (CNTO 136); RA CNTO 1959: PsO, RA ASP015K: (JAK inhibitor); RA

ZYTIGA: Chemo-nave mCPRC, metastatic breast Siltuximab: Castlemans Disease Ibrutinib: (PCI-32765); B-Cell malignancies Intetumumab: (CNTO 95); Melanoma Daratumumab: Multiple Myeloma

Simeprevir: (TMC435); Hepatitis C Bedaquiline: MDR TB Flucell: Influenza

1. Phase 2 studies in cancer pain ongoing 2. Discussions with FDA in progress regarding phase 3 studies for other pain indications

37

Creating Value Through Innovation

Exciting Late Stage Pipeline of New, Differentiated Medicines
NEUROSCIENCE CARDIOVASCULAR & METABOLISM
IMMUNOLOGY

ONCOLOGY

INFECTIOUS DISEASES & VACCINES

INVEGA SUSTENNA: (3 month formulation) Schizophrenia Fulranumab1,2: Pain

XARELTO: VTE, ACS Canagliflozin: Type 2 diabetes, fixed dose combination with Metformin

SIMPONI: RA (IV), UC & JIA STELARA: PsA, CD & RA Sirukumab: (CNTO 136); RA CNTO 1959: PsO, RA ASP015K: (JAK inhibitor); RA

ZYTIGA: Chemo-nave mCPRC, metastatic breast Siltuximab: Castlemans Disease Ibrutinib: (PCI-32765); B-Cell malignancies Intetumumab: (CNTO 95); Melanoma Daratumumab: Multiple Myeloma

Simeprevir: (TMC435); Hepatitis C Bedaquiline: MDR TB Flucell: Influenza

1. Phase 2 studies in cancer pain ongoing 2. Discussions with FDA in progress regarding phase 3 studies for other pain indications

38

Canagliflozin
A Novel SGLT2 Inhibitor for Type 2 Diabetes
Oral, once-daily Shown in studies to lower glucose and contribute to weight loss Potential first choice for add-on therapy to metformin Development Timeline: Phase 3 program enrolled over 10,300 patients across a spectrum of patients with type 2 diabetes
CANVAS Prospective cardiovascular safety study evaluating over 4,300 patients Insulin sub-study presented at the European Association for the Study of Diabetes (EASD) Ongoing post approval cardiovascular safety analysis

US filing, May 31, 2012; EU filing, June 26, 2012

5 additional filings submitted worldwide through Q3

Additional Indication: Fixed dose combination with metformin

39

Simeprevir (TMC435)
Potential Best-in-Class Protease Inhibitor for Chronic Hepatitis C
One pill once daily dosing Co-development with Medivir Significantly improved viral cure rates in phase 2b studies
Treatment-nave and treatment-failure patients

Development Timeline: Global phase 3 studies ongoing

2 in nave patients and 1 in relapsing patients 1 in non-responder population Phase 3 studies also ongoing in Japan

WW rights except the Nordics Interferon free combination regimens being studied
2 studies in phase 2: in combination with GS7977 and BMS790052

Targeted filing 1H 2013 US, EU and Japan

40

Ibrutinib (PCI-32765)
First-in-Class Brutons tyrosine kinase (Btk) Inhibitor for B-Cell Malignancies
Collaboration with Pharmacyclics, Inc.
Co-development and co-commercialization

New form of oral therapy for patients with B-Cell malignancies Multiple potential indications: Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia, Follicular Lymphoma, Diffuse Large B-Cell Lymphoma, Multiple Myeloma Development Timeline: Multiple studies enrolling now
Phase 2 study in MCL Two phase 3 studies for relapsed and refractory CLL

41

Creating Value Through Innovation

Significant Line Extensions: Pipelines in a Product
NEUROSCIENCE CARDIOVASCULAR & METABOLISM
IMMUNOLOGY

ONCOLOGY

INFECTIOUS DISEASES & VACCINES

INVEGA SUSTENNA: (3 month formulation) Schizophrenia Fulranumab1,2: Pain

XARELTO: VTE, ACS Canagliflozin: Type 2 diabetes, fixed dose combination with Metformin

SIMPONI: RA (IV), UC & JIA STELARA: PsA, CD & RA Sirukumab: (CNTO 136); RA CNTO 1959: PsO, RA ASP015K: (JAK inhibitor); RA

ZYTIGA: Chemo-nave mCPRC, metastatic breast Siltuximab: Castlemans Disease Ibrutinib: (PCI-32765); B-Cell malignancies Intetumumab: (CNTO 95); Melanoma Daratumumab: Multiple Myeloma

Simeprevir: (TMC435); Hepatitis C Bedaquiline: MDR TB Flucell: Influenza

1. Phase 2 studies in cancer pain ongoing 2. Discussions with FDA in progress regarding phase 3 studies for other pain indications

42

Creating Value Through Innovation

Significant Line Extensions: Pipelines in a Product
NEUROSCIENCE CARDIOVASCULAR & METABOLISM
IMMUNOLOGY

ONCOLOGY

INFECTIOUS DISEASES & VACCINES

INVEGA SUSTENNA: (3 month formulation) Schizophrenia Fulranumab1,2: Pain

XARELTO: VTE, ACS Canagliflozin: Type 2 diabetes, fixed dose combination with Metformin

SIMPONI: RA (IV), UC & JIA STELARA: PsA, CD & RA Sirukumab: (CNTO 136); RA CNTO 1959: PsO, RA ASP015K: (JAK inhibitor); RA

ZYTIGA: Chemo-nave mCPRC, metastatic breast Siltuximab: Castlemans Disease Ibrutinib: (PCI-32765); B-Cell malignancies Intetumumab: (CNTO 95); Melanoma Daratumumab: Multiple Myeloma

Simeprevir: (TMC435); Hepatitis C Bedaquiline: MDR TB Flucell: Influenza

1. Phase 2 studies in cancer pain ongoing 2. Discussions with FDA in progress regarding phase 3 studies for other pain indications

43

Creating Value Through Innovation

NEUROSCIENCE CARDIOVASCULAR & METABOLISM

Multiple New Partnership Models to Access External Innovation

NEUROSCIENCE

IMMUNOLOGY

ONCOLOGY

INFECTIOUS DISEASES & VACCINES

PLATFORMS and DIAGNOSTICS

44

Creating Value Through Innovation

NEUROSCIENCE CARDIOVASCULAR & METABOLISM

Multiple New Partnership Models to Access External Innovation

NEUROSCIENCE

IMMUNOLOGY

ONCOLOGY

INFECTIOUS DISEASES & VACCINES

PLATFORMS and DIAGNOSTICS

45

Extending Global Reach with Local Focus

Accessing External Innovation Through J&J Innovation Centers

Scientific expertise Deal making capabilities Business expertise

Innovation center

Academia Small Biotech Consortia VCs

Located at worlds leading innovation hot spots

46

Extending Global Reach with Local Focus

Accessing External Innovation Through J&J Innovation Centers

London San Francisco Boston Shanghai

47

Excellence in Execution
Leveraging Global Operational Excellence
World class development capabilities
Successful execution of multiple large clinical programs Industry-leading benchmark timelines for filings and submissions

Ability to develop, file and launch drugs simultaneously across the globe Accelerating pipelines in China and Japan Excellence in safety surveillance
Leveraging of global footprint to deliver around-the-clock pharmacovigilance Assuring pan-lifecycle, global safety risk management for every product

Industry leading NME success rates with fastest cycle time*

Result: Lower cost/NME vs. industry median*

* Proprietary research 48

Leading with Purpose

Health: the basis of our business Years of lives saved and quality of life improved
Enhancing broad and global access to medicines Facilitating developing world access to HIV therapies Significant donor of de-worming medications for children in the developing world

Bringing the power of science for global health

Bedaquiline (TMC207): TB drug dev with TB Alliance TMC120: Vaginal Microbicide, royalty-free license to (IPM) EDURANT (TMC278) LA: Collaboration with Gates Foundation Vaccines

49

Our Strategy Is Delivering

Industry-leading portfolio Driving growth from core brands, and achieving strong growth from new products Deep expertise and world class capabilities Operational excellence to deliver globally and competitively Creating value for society Bringing business back to growth
50

Questions and Answers

51

Dominic Caruso
Vice President, Finance and Chief Financial Officer

52

53